YS Biopharma Co Performance
The firm owns a Beta (Systematic Risk) of 0.0, which attests to not very significant fluctuations relative to the market. the returns on MARKET and YS Biopharma are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days YS Biopharma Co has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, YS Biopharma is not utilizing all of its potentials. The latest stock price uproar, may contribute to short-horizon losses for the private investors. ...more
YS Biopharma |
YS Biopharma Relative Risk vs. Return Landscape
If you would invest (100.00) in YS Biopharma Co on October 11, 2025 and sell it today you would earn a total of 100.00 from holding YS Biopharma Co or generate -100.0% return on investment over 90 days. YS Biopharma Co is generating negative expected returns and assumes 0.0% volatility on return distribution over the 90 days horizon. Put differently, 0% of stocks are less risky than YS Biopharma on the basis of their historical return distribution, and some 99% of all equities are expected to be superior in generating returns on investments over the next 90 days. Expected Return |
| Risk |
YS Biopharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for YS Biopharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as YS Biopharma Co, and traders can use it to determine the average amount a YS Biopharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| High Returns | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| YS |
Based on monthly moving average YS Biopharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of YS Biopharma by adding YS Biopharma to a well-diversified portfolio.
YS Biopharma Fundamentals Growth
YS Biopharma Stock prices reflect investors' perceptions of the future prospects and financial health of YS Biopharma, and YS Biopharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on YS Biopharma Stock performance.
| Return On Equity | -0.78 | |||
| Return On Asset | -0.1 | |||
| Profit Margin | (0.67) % | |||
| Operating Margin | (0.49) % | |||
| Current Valuation | 429.47 M | |||
| Shares Outstanding | 188.33 M | |||
| Price To Book | 2.10 X | |||
| Price To Sales | 0.29 X | |||
| Revenue | 687.2 M | |||
| EBITDA | (76.82 M) | |||
| Total Debt | 498.63 M | |||
| Book Value Per Share | 5.10 X | |||
| Cash Flow From Operations | (182.47 M) | |||
| Earnings Per Share | (0.56) X | |||
| Total Asset | 1.72 B | |||
| Retained Earnings | (1.87 B) | |||
Things to note about YS Biopharma performance evaluation
Checking the ongoing alerts about YS Biopharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for YS Biopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| YS Biopharma is not yet fully synchronised with the market data | |
| YS Biopharma has some characteristics of a very speculative penny stock | |
| YS Biopharma has a very high chance of going through financial distress in the upcoming years | |
| The company generated the yearly revenue of 687.2 M. Annual Net Loss to common stockholders was (145.48 M) with gross profit of 0. | |
| YS Biopharma generates negative cash flow from operations | |
| About 81.0% of the company outstanding shares are owned by insiders |
- Analyzing YS Biopharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether YS Biopharma's stock is overvalued or undervalued compared to its peers.
- Examining YS Biopharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating YS Biopharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of YS Biopharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of YS Biopharma's stock. These opinions can provide insight into YS Biopharma's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Current Watchlist to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Other Consideration for investing in YS Biopharma Stock
If you are still planning to invest in YS Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the YS Biopharma's history and understand the potential risks before investing.
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |